UNII 593YOG76RN

SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

Unique Ingredient Identifier 593YOG76RN is listed as a ingredient substance
Unii593YOG76RN
Preferred Substance NameSODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
Rn10049-21-5
NcitC61947
Rxcui221125
Pubchem516949
Molecular FormulaNa.H2O.H2O4P
InchikeyBBMHARZCALWXSL-UHFFFAOYSA-M
SmilesO.[Na+].OP(O)([O-])=O
Unii TypeINGREDIENT SUBSTANCE
RN10049-21-5
NCITC61947
RXCUI221125
PUBCHEM516949
MFNa.H2O.H2O4P
INCHI KEYBBMHARZCALWXSL-UHFFFAOYSA-M
SMILESO.[Na+].OP(O)([O-])=O

Alternate Names

Dosage Forms

UNII 593YOG76RN SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE is commonly included in medications in the following forms.

RouteDosage FormPotency
IM - IVINJECTABLE0.18 %
IM - IVINJECTION0.5 %
IM - IVPOWDER1.56 %
IM - IVPOWDER, FOR INJECTION SOLUTION0.18 %
INTRA-ARTICULARINJECTABLE0.34 %
INTRALESIONALINJECTABLE0.68 %
INTRAMUSCULARINJECTABLE0.68 %W/V
INTRAMUSCULARINJECTION5 mg/1mL
INTRAMUSCULARINJECTION0.15 %W/V
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED NA
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH 0.14 %
INTRAMUSCULARSUSPENSION, INJECTION0.38 %W/V
INTRASYNOVIALINJECTABLE0.68 %
INTRAVASCULARINJECTION NA
INTRAVENOUSINJECTABLE1.8 mg/mL
INTRAVENOUSINJECTION6.21 %
INTRAVENOUSINJECTION5 mg/1mL
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION0.05 %
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED0.05 %
INTRAVENOUSSOLUTION, INJECTION0.54 %
INTRAVESICALSOLUTION NA
INTRAVITREALINJECTABLE0.86 %
IV(INFUSION)INJECTION0.5 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION1.36 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION, LYOPHILIZED0.02 %
OPHTHALMICDROPS0.041 %
OPHTHALMICSOLUTION0.72 %
OPHTHALMICSOLUTION, DROPS0.72 %
OPHTHALMICSOLUTION/DROPS1.3 %
OPHTHALMICSUSPENSION0.54 %
ORALCAPSULE600 MG
ORALORAL SOLUTION DOSAGE FORM30 mg/5mL
ORALSOLUTION258 MG/20ML
ORALSUSPENSION37.5 MG/5ML
ORALSYRUP20.6 MG/5ML
ORALTABLET31.72 MG
ORALTABLET, DELAYED ACTION, ENTERIC COATED35 MG
ORALTABLET, FILM COATED0.11 MG
SUBCUTANEOUSINJECTABLE0.036 %
SUBCUTANEOUSINJECTION0.12 %
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED0.064 %
TOPICALCREAM0.3 %W/W
TOPICALEMULSION, CREAM0.3 %W/W
TOPICALLOTION0.27 %W/W
TOPICALLOTION, AUGMENTED0.15 %W/W
TOPICALSOLUTION0.46 %W/V
TOPICALSOLUTION, DROPS0.46 %W/V
URETERALSOLUTION NA

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.